INFEX Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections

Alderley Park, Cheshire, U.K. – 12 May 2026, Infex Therapeutics, a leading anti-infectives specialist, announces it has secured £4.3 million in funding led by prominent British venture capitalist Jon Moulton, with participation from the GM&C Life Sciences Fund (managed by Catapult Ventures) and existing high net worth investors.

The funding will support the continued advancement of Infex’s pipeline of novel anti-infectives targeting antimicrobial resistance (AMR) and other critical-priority infectious diseases. Specifically, the investment will enable:

• Preparation for further clinical development of RESP-X, following completion of its encouraging Phase 2a trial in Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB) patients;
• Expansion of the MET-X programme, a resistance bypass treatment targeting Gram-negative Enterobacterales, for drug-resistant infections, alongside the Company’s clinical development partnership with Venus Remedies Ltd (“Venus”) in India, and;
• Progression of preclinical programmes, including its first-in-class BamA inhibitor being developed in collaboration with Justus-Liebig-University Giessen.

“We are delighted to secure this investment led by Jon Moulton, with support from the Greater Manchester and Cheshire Lifescience Investment Fund and our existing investors,” said Dr Peter Jackson, CEO of Infex Therapeutics. “This funding represents strong validation of our progress in developing novel anti-infectives to address the critical global threat of antimicrobial resistance. It enables us to advance RESP-X toward later stage clinical development, expand our MET-X programme, and advance our broader preclinical pipeline of first-in-class approaches targeting highly resistant Gram-negative pathogens.”

Jon Moulton, Chair of Infex Therapeutics, commented: “We have supported Infex from the beginning and continue to be impressed by the Company’s scientific progress and strategic execution. Infex’s lead programme RESP-X is approaching a critical inflection point with upcoming phase IIa results, and we strongly believe it will be a life-changing future first therapy for NCFB patients with drug resistant Pa colonisation. This additional investment reflects our strong conviction in both the team and its innovative approach to tackling antimicrobial resistance.

Nick Wright, CEO of Catapult Ventures, which manages the GM&C Life Sciences Fund, said: “Infex Therapeutics has made excellent scientific progress since we first invested several years ago. The company has clearly established itself as a world leader in the AMR and related space and the data it is generating is very compelling.”